Immatics (NASDAQ:IMTX - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 9,570,000 shares, a growth of 13.1% from the December 15th total of 8,460,000 shares. Based on an average daily trading volume, of 772,000 shares, the days-to-cover ratio is currently 12.4 days.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in IMTX. HighVista Strategies LLC acquired a new position in shares of Immatics in the second quarter valued at $904,000. Vestal Point Capital LP raised its stake in shares of Immatics by 36.4% in the 3rd quarter. Vestal Point Capital LP now owns 3,750,000 shares of the company's stock valued at $42,788,000 after buying an additional 1,000,000 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Immatics in the 2nd quarter valued at $13,392,000. abrdn plc bought a new position in shares of Immatics during the 3rd quarter worth about $2,657,000. Finally, Wellington Management Group LLP boosted its position in shares of Immatics by 1.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,681,183 shares of the company's stock valued at $110,462,000 after acquiring an additional 144,549 shares in the last quarter. Institutional investors and hedge funds own 64.41% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently issued reports on IMTX. The Goldman Sachs Group raised shares of Immatics to a "strong-buy" rating in a report on Monday, November 25th. Piper Sandler started coverage on shares of Immatics in a report on Monday, October 7th. They set an "overweight" rating and a $19.00 price target for the company. Finally, Bank of America dropped their price objective on Immatics from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, November 19th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Immatics has a consensus rating of "Buy" and an average price target of $16.67.
Check Out Our Latest Report on Immatics
Immatics Price Performance
IMTX stock traded up $0.01 on Friday, reaching $5.35. 1,060,755 shares of the company were exchanged, compared to its average volume of 836,641. Immatics has a 12 month low of $5.28 and a 12 month high of $13.77. The stock's fifty day moving average price is $7.35 and its 200 day moving average price is $9.84. The firm has a market capitalization of $638.58 million, a PE ratio of -8.11 and a beta of 0.77.
About Immatics
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Further Reading
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
